Investing.com - Financial Markets Worldwide
Open in App

Macro Group Pharmaceutical SAE (MCRO)

Egypt
Currency in EGP
1.68
-0.03(-1.75%)
Closed·

MCRO Income Statement

Period Ending:
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
2025
31/12
Total Revenues
aa.aa594.26729.61526.01519.97894.54
Total Revenues Growth
aa.aa+38.04%+22.78%-27.91%-1.15%+72.04%
Cost Of Revenues
aa.aa120.39167.97230.36196.85285.3
Gross Profit
aa.aa473.87561.64295.65323.12609.24
Gross Profit Growth
aa.aa+40.14%+18.52%-47.36%+9.29%+88.55%
Gross Profit Margin %
aa.aa79.74%76.98%56.21%62.14%68.11%
Other Operating Expenses, Total
aa.aa270.25327.29478.04311.09473.79
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
aa.aa+72.58%+21.11%+46.06%-34.92%+52.3%
aa.aa-----
aa.aa256.52317.33451.46310.5457.93
aa.aa13.739.9626.570.5915.86
Operating Income
aa.aa203.62234.35-182.3912.03135.45
Operating Income Growth
aa.aa+12.16%+15.09%-177.83%+106.6%+1,025.85%
EBIT Margin %
aa.aa34.26%32.12%-34.67%2.31%15.14%
Net Interest Expenses
aa.aa-7.09-10.68-27.5-54.88-25.04
Net Interest Expenses Growth
aa.aa-428.31%-50.52%-157.59%-99.53%+54.37%
Interest Expense, Total
aa.aa-8.15-13.48-29.48-60.65-34.43
Interest And Investment Income
aa.aa1.062.81.985.779.39
Other Non Operating Expenses, Total
aa.aa-0.063.68-35.72-11.48
EBT, Excl. Unusual Items
aa.aa196.46227.35-245.62-42.85121.89
Gain (Loss) On Sale Of Assets
aa.aa-----
Other Unusual Items, Total
aa.aa---3--
EBT, Incl. Unusual Items
aa.aa196.46227.35-270.03-39.56121.89
EBT, Incl. Unusual Items Growth
aa.aa+10.58%+15.72%-218.77%+85.35%+408.15%
EBT, Incl. Unusual Items Margin
aa.aa33.06%31.16%-51.34%-7.61%13.63%
Income Tax Expense
aa.aa48.4953.482.6-1.516.07
Net Income to Company
aa.aa147.97173.88-272.64-38.04115.82
Minority Interest
aa.aa-0.04-0.04-0.01-0.05-0.09
Net Income
aa.aa147.93173.84-272.65-38.1115.73
Net Income Growth
aa.aa+9.47%+17.51%-256.84%+86.03%+403.76%
Net Income Margin %
aa.aa24.89%23.83%-51.83%-7.33%12.94%
Preferred Dividend and Other Adjustments
aa.aa-----
Net Income to Common Excl. Extra Items
aa.aa147.93173.84-272.65-38.1115.73
Basic EPS - Continuing Operations
aa.aa0.260.3-0.48-0.070.2
Basic EPS - Continuing Operations Growth
aa.aa+9.47%+18.56%-259.17%+86.18%+403.76%
Diluted EPS - Continuing Operations
aa.aa0.260.3-0.48-0.070.2
Diluted EPS - Continuing Operations Growth
aa.aa+11.4%+17.09%-261.17%+85.52%+385.71%
Basic Weighted Average Shares Outstanding
aa.aa577.36572.26563.9570.21570.21
Diluted Weighted Average Shares Outstanding
aa.aa577.36572.26563.9570.21570.21
Dividend Per Share
aa.aa0.070.11---
Dividend Per Share Growth
aa.aa-+54.7%---
EBITDA
aa.aa206.04237.89-175.1916.6140.42
EBITDA Growth
aa.aa+12.29%+15.46%-173.64%+109.48%+745.92%
EBITDA Margin %
aa.aa34.67%32.61%-33.31%3.19%15.7%
EBIT
aa.aa203.62234.35-182.3912.03135.45
* In Millions of EGP (except for per share items)

FAQ

What was Macro Pharmaceutical’s revenue at year end?

At the end of the last reported fiscal year, Macro Pharmaceutical (MCRO) recorded total revenue of 894.54 million EGP.

How much revenue did Macro Pharmaceutical report in the most recent quarter?

In its most recent quarterly earnings report, Macro Pharmaceutical posted revenue of 216.28 million EGP.

What was Macro Pharmaceutical’s net income for the year?

For the full year, Macro Pharmaceutical reported net income of 115.73 million EGP.

How much net income did Macro Pharmaceutical post in the last quarter?

In the most recent quarter, Macro Pharmaceutical (MCRO) posted net income of 11.84 million EGP.

What was Macro Pharmaceutical’s gross profit for the year?

Gross profit for the year was reported at 609.24 million EGP.

How much gross profit did Macro Pharmaceutical generate last quarter?

Macro Pharmaceutical recorded gross profit of 145.15 million EGP in its latest quarterly report.

What was Macro Pharmaceutical’s annual operating income?

For the full year, Macro Pharmaceutical (MCRO) reported operating income of 135.45 million EGP.

What was Macro Pharmaceutical’s operating income last quarter?

Quarterly operating income was 20.49 million EGP.

What was Macro Pharmaceutical’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at 21.82 million EGP.

What was the quarter-over-quarter change in EBITDA for Macro Pharmaceutical?

EBITDA changed by -39.20% million EGP compared to the last quarter.

What is Macro Pharmaceutical’s most recent gross profit margin?

The latest reported gross profit margin for Macro Pharmaceutical (MCRO) is 67.11% million EGP.

What is Macro Pharmaceutical’s most recent net income margin?

Net income margin based on recent financials is 5.47% million EGP.

What is Macro Pharmaceutical’s most recent EBIT margin?

Macro Pharmaceutical reported an EBIT margin of 9.47% million EGP based on current figures.

How did Macro Pharmaceutical’s revenue change compared to the previous quarter?

Revenue changed by -18.91% million EGP compared to the prior quarter.

What was the quarter-over-quarter change in gross profit for Macro Pharmaceutical?

In the latest quarter, gross profit changed by -21.03% million EGP from the previous quarter.
Install Our App
Follow us
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.